WeLeader Biomedical Co. Ltd. (7713) Stock Statistics & Valuation Metrics
Total Valuation
WeLeader Biomedical Co. Ltd. has a market cap or net worth of TWD 3.21B. The enterprise value is TWD 4.61B.
- Market Cap
- TWD 3.21B
- Enterprise Value
- TWD 4.61B
Share Statistics
WeLeader Biomedical Co. Ltd. has 45,478,844 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 45,478,844
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
WeLeader Biomedical Co. Ltd.’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 9.83%.
- Return on Equity (ROE)
- 0.17
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 9.83%
- Return on Capital Employed (ROCE)
- 0.13
- Revenue Per Employee
- 5.31M
- Profits Per Employee
- 997.87K
- Employee Count
- 209
- Asset Turnover
- 0.45
- Inventory Turnover
- 6.26
Valuation Ratios
The current PE Ratio of WeLeader Biomedical Co. Ltd. is 12.86. WeLeader Biomedical Co. Ltd.’s PEG ratio is 0.37.
- PE Ratio
- 12.86
- PS Ratio
- 2.66
- PB Ratio
- 2.67
- Price to FCF
- 17.45
- Price to Operating Cash Flow
- 9.73
- PEG Ratio
- 0.37
Income Statement
In the last 12 months, WeLeader Biomedical Co. Ltd. had revenue of 1.11B and earned 208.56M in profits. Earnings per share was 4.64.
- Revenue
- 1.11B
- Gross Profit
- 370.97M
- Operating Income
- 261.22M
- Pretax Income
- 260.98M
- Net Income
- 208.56M
- EBITDA
- 384.25M
- Earnings Per Share (EPS)
- 4.64
Cash Flow
In the last 12 months, operating cash flow was 329.16M and capital expenditures -145.15M, giving a free cash flow of 184.01M billion.
- Operating Cash Flow
- 329.16M
- Free Cash Flow
- 184.01M
- Free Cash Flow per Share
- 4.06
Dividends & Yields
WeLeader Biomedical Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of 5.82%
- Dividend Per Share
- ―
- Dividend Yield
- 5.82%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 5.74%
- Earnings Yield
- 7.79%
Stock Price Statistics
- Beta
- 0.27
- 52-Week Price Change
- -5.37%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 25.23
- Average Volume (3m)
- 7,934
Important Dates
WeLeader Biomedical Co. Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
WeLeader Biomedical Co. Ltd. as a current ratio of 1.81, with Debt / Equity ratio of 68.54%
- Current Ratio
- 1.81
- Quick Ratio
- 1.53
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- 1.63
- Interest Coverage Ratio
- 32.58
Taxes
In the past 12 months, WeLeader Biomedical Co. Ltd. has paid 52.43M in taxes.
- Income Tax
- 52.43M
- Effective Tax Rate
- 0.20
Enterprise Valuation
WeLeader Biomedical Co. Ltd. EV to EBITDA ratio is 9.28, with an EV/FCF ratio of 22.25.
- EV to Sales
- 3.39
- EV to EBITDA
- 9.28
- EV to Free Cash Flow
- 22.25
- EV to Operating Cash Flow
- 12.44
Balance Sheet
WeLeader Biomedical Co. Ltd. has TWD 122.73M in cash and marketable securities with TWD 978.95M in debt, giving a net cash position of -TWD 856.22M billion.
- Cash & Marketable Securities
- TWD 122.73M
- Total Debt
- TWD 978.95M
- Net Cash
- -TWD 856.22M
- Net Cash Per Share
- -TWD 18.83
- Tangible Book Value Per Share
- TWD 26.34
Margins
Gross margin is 35.09%, with operating margin of 25.63%, and net profit margin of 20.61%.
- Gross Margin
- 35.09%
- Operating Margin
- 25.63%
- Pretax Margin
- 25.65%
- Net Profit Margin
- 20.61%
- EBITDA Margin
- 36.51%
- EBIT Margin
- 25.75%
Analyst Forecast
The average price target for WeLeader Biomedical Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 19.20%
- EPS Growth Forecast
- 34.00%
